Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment.

[1]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[2]  P. Diest,et al.  Hypoxia-inducible factor-1α expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas , 2006, Oncogene.

[3]  T. Ward,et al.  Hypoxia in head and neck cancer. , 2006, The British journal of radiology.

[4]  V. Haase,et al.  The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. , 2006, Kidney international.

[5]  K. O'Byrne,et al.  Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. , 2006, Clinical lung cancer.

[6]  A. Heerschap,et al.  Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas , 2006, Investigational New Drugs.

[7]  B. Freedman,et al.  Hypoxia inducible factor 1α regulates T cell receptor signal transduction , 2005 .

[8]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[9]  Hiroshi Nakamura,et al.  TCR Engagement Increases Hypoxia-Inducible Factor-1α Protein Synthesis via Rapamycin-Sensitive Pathway under Hypoxic Conditions in Human Peripheral T Cells1 , 2005, The Journal of Immunology.

[10]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[11]  P. Johnston,et al.  Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life , 2005, Oncology.

[12]  Daniel J Brat,et al.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. , 2005, Neuro-oncology.

[13]  L. Herzenberg,et al.  Culturing at atmospheric oxygen levels impacts lymphocyte function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Sitkovsky,et al.  Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. , 2005, Nature reviews. Immunology.

[15]  L. Cooper,et al.  Induction of Therapeutic T-Cell Responses to Subdominant Tumor-associated Viral Oncogene after Immunization with Replication-incompetent Polyepitope Adenovirus Vaccine , 2004, Cancer Research.

[16]  Y. Okada,et al.  Hypoxia-Inducible Factor Regulates Survival of Antigen Receptor-Driven T Cells 1 , 2003, The Journal of Immunology.

[17]  M. Dewhirst,et al.  Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.

[18]  K. Gatter,et al.  Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma , 2003, British Journal of Cancer.

[19]  M. Petrović,et al.  Hypoxia Regulates Expression and Activity of Kv1.3 Channels in T Lymphocytes: A Possible Role in T Cell Proliferation1 , 2003, The Journal of Immunology.

[20]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[22]  Erwin G. Van Meir,et al.  Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1 , 2002, Oncogene.

[23]  J. Hanly,et al.  IFN-γ-Inducible T Cell α Chemoattractant Is a Potent Stimulator of Normal Human Blood T Lymphocyte Transendothelial Migration: Differential Regulation by IFN-γ and TNF-α1 , 2002, The Journal of Immunology.

[24]  A. Harris,et al.  Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non‐Hodgkin's lymphoma , 2002, Histopathology.

[25]  H. Heslop,et al.  Immunotherapy for Hodgkin's disease. , 2002, Annals of hematology.

[26]  A. Ohta,et al.  Differential Regulation of Two Alternatively Spliced Isoforms of Hypoxia-inducible Factor-1α in Activated T Lymphocytes* , 2001, The Journal of Biological Chemistry.

[27]  M. Sitkovsky,et al.  Differential Effects of Physiologically Relevant Hypoxic Conditions on T Lymphocyte Development and Effector Functions , 2001, The Journal of Immunology.

[28]  Erwin G. Van Meir,et al.  Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells , 2001, Gene Therapy.

[29]  B. Harder,et al.  Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. , 2001, Human gene therapy.

[30]  M. Dewhirst,et al.  Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. , 2001, American journal of physiology. Heart and circulatory physiology.

[31]  A. Harris,et al.  Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[33]  T. Strom,et al.  IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.

[34]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[35]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[36]  R. Krance,et al.  Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. , 1998, Human gene therapy.

[37]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[38]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[39]  H. Lederman,et al.  Effects of hypoxia on interleukin‐2 mRNA expression by T lymphocytes , 1994, Critical care medicine.

[40]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[41]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[42]  M A Goldberg,et al.  The regulated expression of erythropoietin by two human hepatoma cell lines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Macdonald,et al.  Energy metabolism and T-cell-mediated cytolysis. I. Synergism between inhibitors of respiration and glycolysis , 1977, The Journal of experimental medicine.